Loading clinical trials...
Loading clinical trials...
The aim of the study is to compare the effectiveness of rifaximin versus norfloxacin for secondary prevention of spontaneous bacterial peritonitis in patients with liver cirrhosis and ascites.
Keep your clinical trial research organized — questions to ask, what to expect, and key details.
Lead Sponsor
Sherief Abd-Elsalam
Collaborators
NCT07439939 · Liver Cirrhosis, Portal Hypertension
NCT06680583 · Liver Cirrhosis, Gastrointestinal Bleeding
NCT07437755 · Liver Cirrhosis With Acute Decompensation
NCT06169592 · Liver Cirrhosis, Liver Transplant; Complications
NCT06669806 · Portal Hypertension Related to Cirrhosis, Ascites Hepatic, and more
Tanta university hospital
Tanta
Use Clareo to keep notes, questions, trial details, and next steps organized before and after appointments.
Start free trial →Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions